1 studied in the presence of a select group of
cannabimimetics.
2 These results indicate that
cannabimimetics act presynaptically to inhibit the relea
3 ological assays for potential enhancement of
cannabimimetic activities.
4 bind to the cannabinoid receptor and possess
cannabimimetic activity yet are structurally dissimilar
5 sts in mouse behavioral assays indicative of
cannabimimetic activity, including antinociception, hypo
6 e indole ring in compound 1 is essential for
cannabimimetic activity.
7 n aliphatic hydroxyl (SAH) pharmacophore for
cannabimimetic activity.
8 oups may be a characteristic requirement for
cannabimimetic activity.
9 ize harmful side effects of cannabinoids and
cannabimimetic agents.
10 aS to G-proteins and were shown to be potent
cannabimimetic agonists.
11 onship) models (CoMFA models 1 and 2) of the
cannabimimetic (
aminoalkyl)indoles (AAIs) for CB1 cannab
12 ether (2-AGE), and anandamide (AEA)] and the
cannabimimetic aminoalkylindole WIN 55,212-2 (WIN) inhib
13 The
cannabimimetic aminoalkylindole WIN 55,212-2 inhibited w
14 mmodate a wide range of structurally diverse
cannabimimetic analogues including the AAIs.
15 Several analogs of an endogenous
cannabimimetic,
arachidonylethanolamide (anandamide), we
16 and lipoxygenase and is mediated in part by
cannabimimetic CB1 receptor, G protein, phosphoinositol
17 Anandamide, the endogenous
cannabimimetic compound, had an inconsistent effect on t
18 axant 2-arachidonoyl glycerol, an endogenous
cannabimimetic derivative of arachidonic acid.
19 In contrast,
cannabimimetics did not affect bicuculline-sensitive inh
20 The
cannabimimetic drug Win55212-2 (100 nM) completely block
21 The
cannabimimetic drug, Win 55212-2 (300 nM), inhibited FM1
22 Cannabimimetic drugs are of particular relevance to HAD
23 Cannabimimetic drugs did not protect cells from the dire
24 These data suggest that
cannabimimetic drugs may slow the progression of neurode
25 Cannabimimetic drugs prevented the recruitment of new sy
26 tiallodynic effects, possible tolerance, and
cannabimimetic effects (e.g., hypothermia, catalepsy, CB
27 inistered in vivo, it induces only transient
cannabimimetic effects as a result of its rapid cataboli
28 B2 receptors; however, unwanted CB1-mediated
cannabimimetic effects limit clinical use.
29 B1 receptors with a significant reduction of
cannabimimetic effects of CB1 agonists.
30 atory and neuropathic pain without producing
cannabimimetic effects or physical dependence.
31 to reduce excitotoxicity, we tested several
cannabimimetics in a model of synaptically mediated neur
32 and to search for more selective and potent
cannabimimetic ligands.
33 t may participate in maintaining a supply of
cannabimimetic N-acylethanolamines during synaptic activ
34 action of the southern aliphatic hydroxyl of
cannabimimetic pharmacophores with the CB1 and CB2 recep
35 12-2, a synthetic cannabinoid that possesses
cannabimimetic properties, acts as a novel regulator of
36 ding to cannabinoid receptors and of evoking
cannabimimetic responses.
37 iallodynic efficacy, possible tolerance, and
cannabimimetic side effects of repeated dosing with a CB
38 hic and inflammatory pain with minimal or no
cannabimimetic side effects.
39 rawal efficacy, but is accompanied with some
cannabimimetic side effects.
40 al body weight loss), but did not elicit any
cannabimimetic side effects.
41 and the A current, were not modulated by the
cannabimimetic WIN 55,212-2.
42 Superfusion of the
cannabimimetics WIN55212-2 or methanandamide onto CA1 ne